Difference between revisions of "Team:NTU-Singapore/RNA"
| Line 82: | Line 82: | ||
We identified two families of Cas13 proteins to investigate, namely the Cas13b and the Cas13d family. For Cas13b, Feng et. al. (2017) have demostrated its consistently robust knockdown of mRNA in mammalian cell and engineered a dCas13b-ADAR2<span class="small-letter">DD</span> fusion protein to achieve effective site-specific A-to-I editing on mRNA, called the REPAIR (RNA Editing for Programmable A to I Replacement) system. We find their work a great inspiration for our project and we decided to characterise this construct further. <br> | We identified two families of Cas13 proteins to investigate, namely the Cas13b and the Cas13d family. For Cas13b, Feng et. al. (2017) have demostrated its consistently robust knockdown of mRNA in mammalian cell and engineered a dCas13b-ADAR2<span class="small-letter">DD</span> fusion protein to achieve effective site-specific A-to-I editing on mRNA, called the REPAIR (RNA Editing for Programmable A to I Replacement) system. We find their work a great inspiration for our project and we decided to characterise this construct further. <br> | ||
</p> | </p> | ||
| − | <p style="padding-top:0.5em;"> | + | <p style="padding-top:0.5em;padding-botton:1em;"> |
With a basis of comparison established with the REPAIR system, we were also curious about the recently identified Cas13d system (Konermann. et. Al, 2018). With the average size of just 930 amino acids, it is the smallest Class 2 CRIPSR effector ever being characterised in mammalian cells. Despite of its small size, one nuclease-dead variant derived from Ruminococcus flavefaciens XPD3002 (CasRx) has demostrated alternative splicing modulation in vivo with high efficiency and specificity. Hence, we believe it would be interesting and meaningful to compare its A-to-I editing activities when CasRx is fused with the same ADAR2<span class="small-letter">DD</span> domain wih that of REPAIR.<br> | With a basis of comparison established with the REPAIR system, we were also curious about the recently identified Cas13d system (Konermann. et. Al, 2018). With the average size of just 930 amino acids, it is the smallest Class 2 CRIPSR effector ever being characterised in mammalian cells. Despite of its small size, one nuclease-dead variant derived from Ruminococcus flavefaciens XPD3002 (CasRx) has demostrated alternative splicing modulation in vivo with high efficiency and specificity. Hence, we believe it would be interesting and meaningful to compare its A-to-I editing activities when CasRx is fused with the same ADAR2<span class="small-letter">DD</span> domain wih that of REPAIR.<br> | ||
</p> | </p> | ||
Revision as of 01:03, 17 October 2018
RNA Base-Editor
Motivation for RNA Editing
From the results of our human practice, we have seen a great value in RNA editing. First, with the cautious attitude towards gene editing in all three countries we surveyed, many inclines to the reversibility of RNA editing, considering it being safer. Also, professional views from doctors reveal that the high cost of RNA editing results from that in transcriptome analysis and the lack of better RNA modifying protein scaffold. All of our discussions with stakeholders indicate that greater effort should be put to develop RNA editing, while in reality, it is lagging behind its DNA editing counterpart. Hence, we are motivated to develop programmable mRNA-editing analogous to our DNA base-editors as well as realizing cheaper transcriptome analysis by developing better RNA sequencing techniques.
Our DNA base-editors performs two types of base change. One is the C-to-T editing by the enhanced APOBEC1 protein (BE3) fused with Cas9 protein, while the other is the A-T to G-C base pair change by an evolved TadA*-dCas9 fusion protein. The former already has an obvious solution. The APOBEC1 cytidine deaminase in our DNA base-editor was endogenously used and engineered for cytosine-to-uracil editing on mRNA (Petersen-Mahrt, S. K.,2003). Hence, with an RNA-targeting partner, it should naturally induce an equivalent change on mRNA like a C-to-T base change on DNA. Actually, Team NUS-Singapore-Sci is working on such an RNA-targeting C-to-U editor. Hence, we decided to focus our effort on the latter, inducing an equivalent change on mRNA as if an A-to-G base change occurred on DNA.
An Answer through Inosine
While direct A-to-G base change on mRNA is much more difficult, one way to bypass such difficulty is to convert Adenosine to Inosine, which can later be converted to guanosine or allows for pairing with a cytosine. Such an A-to-I editing can be achieved through the adenosine deaminase acting on RNA (ADAR) enzyme family, which mediates endogenous A-to-I modification on mRNA by hydrolytic deamination.
Human has two ADAR orthologues, ADAR1, which targets repetitive regions and ADAR2 which targets non-repetitive coding regions (Tan. et. al., 2017). The latter is a great candidate for targeted A-to-I editing on mRNA. However, as ADAR proteins have preferred motifs on their editing target, a hyperactive mutant of ADAR2 (ADAR2DD), which has its glutamic acid at position 488 replaced by a glutamine (E488Q) (Kuttan. et. al., 2012), is used in our experiment. It has looser target stringency and a higher level of on-target activities.
RNA-Targeting Cas13 Proteins
After the choice of our catalytic domain, we now need to choose an RNA-targeting partner. Previous literature has attempted to engineer ADAR to directly target with RNA guides (Montiel-González, 2016), and such a hybridization-based recognition does not guarantee high specificity and high editing efficiency, Hence, we decided to use a protein partner to assist the target recognition. The recently profiled and characterized Cas13 protein family is our choice.
Cas13 proteins are a family of type VI CRISPR-associated RNA-guided ribonucleases (RNase), which mediates precisely guided mRNA cleavage. These proteins have two higher eukaryotes and prokaryotes nucleotide-binding (HEPN) and RNase domains, and preferred but do not require protospacer flanking sites (PFS) (Abudayyeh. et. al., 2017). As they guided by a single guide RNA to target RNA sequences, their programmable nature allows for targeting specific sites on mRNA and their catalytically inactive versions by mutating conserved catalytic residues in the HEPN domains, dCas13, are then good candidates to fuse with our ADAR proteins to perform site-specific A-to-I editing on mRNA.
Our Two Choices
We identified two families of Cas13 proteins to investigate, namely the Cas13b and the Cas13d family. For Cas13b, Feng et. al. (2017) have demostrated its consistently robust knockdown of mRNA in mammalian cell and engineered a dCas13b-ADAR2DD fusion protein to achieve effective site-specific A-to-I editing on mRNA, called the REPAIR (RNA Editing for Programmable A to I Replacement) system. We find their work a great inspiration for our project and we decided to characterise this construct further.
With a basis of comparison established with the REPAIR system, we were also curious about the recently identified Cas13d system (Konermann. et. Al, 2018). With the average size of just 930 amino acids, it is the smallest Class 2 CRIPSR effector ever being characterised in mammalian cells. Despite of its small size, one nuclease-dead variant derived from Ruminococcus flavefaciens XPD3002 (CasRx) has demostrated alternative splicing modulation in vivo with high efficiency and specificity. Hence, we believe it would be interesting and meaningful to compare its A-to-I editing activities when CasRx is fused with the same ADAR2DD domain wih that of REPAIR.
Experimental Design
Based on Zhang et. al., 2017, we have developed two methods to characterise the functionality and important parameters in designing its guide RNA in mediating A-to-I editing activities, namely by a luciferase reporter assay and sequencing of mRNA of the endogeneous target. In both of our experiments, plasmids coding for dPspCas13b-ADAR2DD and dCas13d-ADAR2DD fusion proteins and different RNA guides to investigate the different targeting parameters were cloned into mammalian expression vectors and transfected into HEK293FT cells. Other important sequences for their functions like the nuclear export signals (NES) were also cloned together with the construct.
Luciferase Reporter Assay
In the luciferase reporter assay, target plasmids coding for a modified Renilla luciferase were constructed, where a guanosine is replced by an adenosine at the codon of a key residue and results in a nonsense mutation. As such, A-to I editing activities later by the dCas-ADAR2DD constructs will the functionally restore the luciferase protein back to the wildtype and allows for the quatification of editing activity by the Rluc flourescnece. In our experiment, two parameters, namely spacer length and regions of coverage on the target were characterised in mediating A-to-I RNA editing.
• Spacer length is the region of guide with homology to the target.
• Regions of target coverage is measured by guide mismatch distance, that is the distance from the 3’-end of the spacer to the base targetting the adenosine to be edited.
In an experiment, the target plasmid, plasmid coding for the dCas-ADAR and plasmid coding for guide RNA are transfected into HEK293FT cells. After 48 hours of transfection, media with the expressed luciferase is harvested and its luminescence was analysed and compared to that of the sample with non-targetting guide, marked as negative. Difference between the two would tell the A-to-I editing efficiency.
Figure 1. Experimental design of luciferase assay
Endogeneous Gene Targeting
With the parameters obtained from the luciferase reporter assay, we further characterised the A-to-I editing activities of the dCas-ADAR2DD constructs on endogeneous genes. In such an experiment, plasmids coding for dPspCas13b-ADAR2DD and dCas13d-ADAR2DD fusion proteins were transfected into HEK293FT cells, together with different guide RNAs targetting endogenous PPIB and KRAS gene. After 48 hours of transfection, transcriptome of the cells were extracted and the target regions were amplified for Sanger sequencing. Fractions of the adenosine being called as guanosine and therefore being edited can then reports for the on-target effieiceny of A-to-I editing. Different guides were used to investigate the activities with different spacer lengths and guide mismatch locations.
Figure 2. Experimental design in endogeneous gene targetting
Results and Discussions
Luciferase Reporter Assay
In the luciferase experiment, we first evaluated the A-to-I editing activities of different RNA editors at different target positions on the Rluc gene. The aforementioned nonsense mutation of G to A was performed and tested at five tryptophan residues, at position 60, 104, 121, 153 and 219 respetively. Figure 3 below shows the luminescence levels after the restoration of Rluc sequence with different editors at different positions.
Figure 3. Editing rate of different RNA editors at different target positions (n = 2)
From the results, we can observed that except for REPAIRv2, other dCas-ADAR2DD constructs showed siginificant A-to-I editing activities on the target and showed different target preferences from dCas13b to dCasRx. For CasRx, editing activities on Rluc W153X is particularly significant. Therefore, it is selected as the target position to investigate the effect of guide length and guide mismatch distance on the A-to-I editing activities.
Figure 4 shows the luminescence levels after the restoration of Rluc sequence by CasRx using guides at different lengths and with different guide-target mismatch distance. The horizontal axis shows the mismatch distance and the number after items in the legend indicates different spacer length.
Table 1. Summary of optimal spacer length and guide mismatch distances
Figure 4. Editing rate of different RNA editors with different spacer lengths and different guide mismatch distances. (n = 2) where dash line shows the non-targetting control
From the results, we were then able to design homolgy-based guides with appropriate spacer length and guide mismatch distances and evaluate the peroformance of A-to-I editing on target mRNA.
Endogeneous Gene Targeting
In this part of the experiment, we used guides to target two different regions of the PPIB and KRAS genes. They were termed as guide 1 and 2 for PPIB and KRAS. Then, some of them will be given a suffix of X.Y, where X indicates the target length and Y indicates the guide mismatch distance. For example, KRAS-1-50.25 is the guide RNA targeting region 1 of KRAS with a spacer length of 50 base-pairs and a mismatch distance of 25 base-pairs. The following results were then obtained from Sanger sequencing. Editing rate is calculated as the area under the guanosine signal in the chromatograph over that of adenosine.
Figure 5. Editing rate of different RNA editors with different spacer lengths and different guide mismatch distances on endogeneous PPIB gene. (n = 2)
Conclusion
Here we have demonstrated Type VI Cas13 proteins can mediate efficient A-to-I base editing on mRNA, for both exogeneous and endogeneous transcript. From both experiments we can conclude that while the optimised REPAIR enzyme showed higher A-to-I editing efficiency, unoptimised dCas13d-ADAR2DD constructs exhibited similar A-to-I editing activity level on mRNA on the PPIB gene. This shows great potential for the dCas13d-ADAR2DD construncts as it has significantly smaller size and there it is still possible for protein engineering and optmisation.
References
1. Harris, R. S., Petersen-Mahrt, S. K., & Neuberger, M. S. (2002). RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular cell, 10(5), 1247-1253.
2. Tan, M. H., Li, Q., Shanmugam, R., Piskol, R., Kohler, J., Young, A. N., ... & Gupte, A. (2017). Dynamic landscape and regulation of RNA editing in mammals. Nature, 550(7675), 249.
3. Montiel-González, M. F., Vallecillo-Viejo, I. C., & Rosenthal, J. J. (2016). An efficient system for selectively altering genetic information within mRNAs. Nucleic acids research, 44(21), e157-e157.
4. Kuttan, A., & Bass, B. L. (2012). Mechanistic insights into editing-site specificity of ADARs. Proceedings of the National Academy of Sciences, 109(48), E3295-E3304.
5. Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., ... & Lander, E. S. (2017). RNA targeting with CRISPR–Cas13. Nature, 550(7675), 280.
6. Cox, D. B., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017). RNA editing with CRISPR-Cas13. Science, 358(6366), 1019-1027.
7. Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018). Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell, 173(3), 665-676.